Vaxart Valuation
Is VXRT * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VXRT * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate VXRT *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VXRT *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VXRT *?
Other financial metrics that can be useful for relative valuation.
What is VXRT *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$125.50m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 15.2x |
Enterprise Value/EBITDA | -1.5x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does VXRT *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 17.1x | ||
4132 Golden Biotechnology | 22x | n/a | NT$4.1b |
DXB Dimerix | 20.5x | n/a | AU$186.9m |
ARX Aroa Biosurgery | 2.8x | 20.6% | AU$166.9m |
CRNO B Cereno Scientific | 23x | -138.5% | kr1.1b |
VXRT * Vaxart | 17x | 50.3% | Mex$125.5m |
Price-To-Sales vs Peers: VXRT * is good value based on its Price-To-Sales Ratio (17x) compared to the peer average (17.1x).
Price to Earnings Ratio vs Industry
How does VXRT *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: VXRT * is expensive based on its Price-To-Sales Ratio (17x) compared to the Global Biotechs industry average (10.8x).
Price to Sales Ratio vs Fair Ratio
What is VXRT *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 17x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate VXRT *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.